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high risk patients.
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PS120.
Are Outcomes of Tibial Artery Atherectomy or Stent-
ing Superior to Tibial Angioplasty Alone Over Time in
the US Medicare Population?
Todd R. Vogel1, Viktor Y. Dombrovskiy1, Paul B. Haser1,
Jeffrey L. Carson2, Alan M. Graham1. 1Department of
Surgery, UMDNJ-Robert Wood Johnson Medical School,
New Brunswick, NJ; 2Department of Medicine, UMDNJ-
Robert Wood Johnson Medical School, New Brunswick, NJ
Objectives: Catheter-based revascularization for the
tibioperoneal vessels is increasingly performed for limb
salvage. Few data are available evaluating longitudinal
outcomes after tibioperoneal angioplasty alone com-
pared to adjunctive tibial procedures including stenting
and atherectomy.
Methods: Patients undergoing percutaneous tibioper-
oneal interventions with a diagnosis of ulceration were iden-
tified using The Centers for Medicare & Medicaid Services
inpatient claims (2005-2007). Patients were grouped: tib-
ioperoneal angioplasty only (TA); tibioperoneal angioplasty
plus stent placement (TAS); and tibioperoneal angioplasty
plus atherectomy (TAA). Complications and longitudinal
amputation rates were evaluated.
Results: 2,080 patients, with a mean age of
77.98.3 years (57.7% male; 79.1% White, 13.3% Black)
underwent tibioperoneal angioplasty for the indication
of ulceration. Procedures included: TA (56.3%), TAS
(16.2%); TAA (27.5%). Overall initial hospital compli-
cations were not significantly different among groups.
Rates of amputation are presented (See Table). Adjusted
for age, gender, race, procedure, and comorbidities, pre-
dictors of 30- and 90-day, and 1-year amputation were
male gender and diabetes. Mean total hospital charges
were: TA ($50,300), TAS ($65,680; P0.0001); TAA
($54,808; P0.057).
Conclusions: Patients undergoing tibioperoneal an-
gioplasty with concomitant stenting or atherectomy during
their initial intervention for ulceration incurred greater
hospital charges and demonstrated no improvement on
amputation rates over time compared to tibial angioplasty
alone. Future trials of adjunctive tibioperoneal intervention Ore essential to temper cost as they fail to improve long term
imb salvage.
ates of Any Amputation Over Time
rocedure
30-day
Amputation
Rate
90-day
Amputation
Rate
1 Year
Amputation
Rate
ibial Angioplasty
(TA) Alone
10.85% 18.79% 28.27%
A  Stent 9.52% 15.18% 24.70%
A  Atherectomy 9.08% 18.15% 28.10%
-Values
NSNon-
Significant
All Differences
NS
All Differences
NS
All Differences
NS
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S122.
rosthetic Conduit is Equivalent to Alternative Vein
ources for Below-Knee Popliteal Bypass Targets in the
bsence of Single Segment Greater Saphenous Vein
ames T. McPhee, Neal R. Barshes, Louis L. Nguyen,
harles K. Ozaki, Michael Belkin. Vascular & Endovascu-
ar Surgery, Brigham & Women’s Hospital, Boston, MA
Objectives: Single segment greater saphenous vein
SSGSV) is the conduit of choice for femoral to below-knee
opliteal bypass (F-BKP). The purpose of this study was to
etermine the optimal conduit in patients with inadequate
SGSV.
Methods: This is a retrospective review of a prospec-
ively maintained vascular registry. Patients underwent F-
KP bypass with either alternative vein (AV) [arm vein/
pliced GSV/composite vein] or prosthetic conduit (PC)
or any indication.
Results: From 01/95-06/10, 85 patients had unus-
ble SSGSV for F-BKP reconstruction. 33 patients had AV
onduit (18.2% arm vein; 81.8% composite)and 52 patients
ad PC (80.8% PTFE, 13.5% Dacron, 1.9% composite and
.8% cryovein). The AV and PC groups had similar mean
ge (68 vs. 72.1, p.08),DM (57.6% vs. 57.7%,
.6),smoking (15.2% vs. 30.8%, p.08), CAD (57.6% vs.
7.3%, p.2), and CLI (93.9% vs. 86.5%, p.2). Most
ere primary bypass attempts for both AV and PC (90.9%
s. 84.6% p0.3). The CFA was the primary inflow for
oth (87.9% vs. 90.4%, p.5). AV and PC groups had
imilar 30 day mortality (3.0% vs. 1.9%, p.6) and major
orbidity (6.1% vs. 7.7%, p.6). PC patients were more
ikely to be placed on Coumadin (p.001). By five-year life
able analysis, there was no significant difference in terms of
rimary, assisted primary, secondary patency or limb sal-
age rates at mean follow up of 1087 and 665 days (Table).
f the 9 failed AV grafts, 7 had new bypass grafts created,
b
p
d
p
p
p
a
o
p
a
A
p
T
r
F
p
s
t
T
n
G
P
W
c
c
J
D
R
C
C
l
C
i
p
r
m
f
e
E
u
d
b
l
t
e
f
p
(
s
JOURNAL OF VASCULAR SURGERY
June Supplement 201162S Abstracts1 had major amputation (11.1%) and 2 were managed
expectantly. Of the 11 failed PC grafts 4(37%) underwent
major amputation, 4 had new bypasses and 3weremanaged
expectantly.
Conclusions: For patients with inadequate SSGSV,
prosthetic conduit is equivalent to alternative vein sources
in terms of graft patency and limb salvage rates for below-
knee popliteal bypass targets.
Primary
Patency
(%)
Assisted
Primary
Patency
(%)
Secondary
Patency
(%)
Limb
Salvage
(%)
Post-op
Coumadin
Usage (%)
Alternative
Vein
54.9  9.9 68.5  9.5 68.4  9.5 96.4  3.6 27.3
Prosthetic
Conduit
54.6  10.5 56  10.6 68.8  9.1 86.0  6.3 61.5
P-value 0.5 0.2 0.5 0.08 0.001
Author Disclosures: N. R. Barshes: Nothing to disclose;
M. Belkin: Nothing to disclose; J. T. McPhee: Nothing to
disclose; L. L. Nguyen: Nothing to disclose; C. K. Ozaki:
Nothing to disclose.
PS124.
Plasmin (Human) TAL-05-00018 Demonstrates a
Good Safety Profile in Patients with Acute Peripheral
Arterial Occlusion
Anthony J. Comerota1, David Fineberg2, Richard Shlan-
sky-Goldberg3, Chunqin Deng4, Victor J. Marder5. 1Jobst
Vascular Center, Toledo, OH; 2Talecris Biotherapeutics,
Research Triangle Park, NC; 3Hospital of the University of
Pennsylvania, Philadelphia, PA; 4Talecris Biotherapeutics,
Research Triangle Park, NC; 5David Geffen School of
Medicine at UCLA, Los Angeles, CA
Objectives: Plasmin is a direct-acting thrombolytic
that has superior hemostatic safety compared to plasmino-
gen activator in preclinical studies. Here, we report safety
data of plasmin in patients with acute peripheral arterial
occlusion (aPAO).
Methods: This was an open-label, Phase I, dose esca-
lation study of Plasmin (human) TAL-05-00018 (Talecris
Biotherapeutics) in patients with SVS Class I or IIa acute
limb ischemia. Sequential 10-13 patient cohorts received a
single,5-hour intrathrombus dose of Plasmin (25 to 175
mg) by multi-slit catheter using manual pulse-spray injec-
tions followed by continuous infusion. Safety was assessed
with clinical evaluations and monitoring of plasma concen-
trations of fibrinogen and alpha 2-antiplasmin inhibitor at
end of plasmin treatment and on days 1-2, 7, 14 and 30.
Results: Of 83 patients enrolled, 19 (22.9%) had seri-
ous adverse events (SAEs) and 57 (68.7%) had treatment-
emergent (TE) adverse events (AEs). Two patients died
(myocardial infarction, sepsis). Four patients had a major
bleeding event and 14 had minor bleeding events. None of
the SAEs, deaths or bleeding events were reported by
investigators to be Plasmin-related. TEAEs, SAEs, and pleeding events did not increase with Plasmin dose. Mean
ost-treatment fibrinogen nadirs were similar at all plasmin
osages (350 - 440 mg/dL). Furthermore, alpha 2-anti-
lasmin inhibitor and fibrinogen levels were similar in
atients with and without bleeding events.
Conclusions: Plasmin treatment (up to 175 mg) of
atients with aPAO had a favorable safety profile, notably
bsence of treatment-related bleeding and maintenance
f normal fibrinogen concentration. These results sup-
ort further clinical trials of Plasmin for treatment of
PAO.
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S126.
ound Infection after Lower Extremity Bypass In-
reases Hospital Resource Utilization But is Not Asso-
iated with Negative Long-Term Outcomes
effrey Kalish1, Alik Farber1, Andres Schanzer2, Gheorghe
oros3, Denis Rybin3, Kevin Tan1, Naomi Hamburg1,
obert Eberhardt1, Jack Cronenwett4. 1Boston Medical
enter, Boston,MA; 2University of Massachusetts Medical
enter,Worcester,MA; 3BostonUniversity School of Pub-
ic Health, Boston, MA; 4Dartmouth-Hitchcock Medical
enter, Lebanon, NH
Objectives: Wound infection (WI) after lower extrem-
ty bypass (LEB) is reported in 5-22% of cases. This com-
lication has been cited by proponents of endovascular
evascularization as a reason to avoid LEB. Although nu-
erous studies have attempted to define predictive risk
actors, long-term effects of WI after LEB have not been
lucidated.
Methods: Using the Vascular Study Group of New
ngland database(2003-2009), we examined 2721 consec-
tive LEB procedures performed by 57 surgeons at aca-
emic and community hospitals. The cohort was stratified
y indication: intermittent claudication (IC) and critical
imb ischemia (CLI). In-hospital WI required documenta-
ion of positive cultures or antibiotic treatment. Primary
ndpoints were ambulation at hospital discharge, 1-year
reedom from major amputation, and 1-year primary
atency.
Results: WI rates were 4.5% (33/734) for IC and 5.5%
109/1987) for CLI. Mean length of stay (LOS) was
ignificantly greater with WI (IC: 3.8 vs 10.1 days,
0.001; CLI: 8.9 vs 13.6 days, p0.001). No signifi-
